These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E; J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia. Bradford PA; Petersen PJ; Tuckman M; Jones CH Clin Microbiol Infect; 2008 Sep; 14(9):882-6. PubMed ID: 18844692 [TBL] [Abstract][Full Text] [Related]
7. [The yield of tigecycline in the treatment of community-acquired pneumonia]. Cilli A Tuberk Toraks; 2013; 61(2):155-61. PubMed ID: 23875595 [TBL] [Abstract][Full Text] [Related]
8. Levofloxacin in the treatment of community-acquired pneumonia. Noreddin AM; Elkhatib WF Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. Koomanachai P; Kim A; Nicolau DP J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050 [TBL] [Abstract][Full Text] [Related]
10. Establishing the role of tigecycline in an era of antimicrobial resistance. Schafer JJ; Goff DA Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395 [TBL] [Abstract][Full Text] [Related]
11. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830 [TBL] [Abstract][Full Text] [Related]
12. The role of new therapies for severe community-acquired pneumonia. Restrepo MI; Anzueto A Curr Opin Infect Dis; 2006 Dec; 19(6):557-64. PubMed ID: 17075331 [TBL] [Abstract][Full Text] [Related]